Iranian Red Crescent Medical Journal

Published by: Kowsar
Crossmark

Serum Calcium and Phosphorus Levels in Hemodialysis Patients: A Large Population-Based Multicenter Study

Mohsen Nafar 1 , Tahereh Sabaghian 2 , 3 , * , Alireza Khoshdel 4 , Behrang Alipour 5 and Shiva Samavat 1
Authors Information
1 Department of Nephrology, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Nephrology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Clinical Epidemiology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
5 Chronic Kidney Disease Research Center (CKDRC), Shahid Labbafinejad Hospital, Tehran, Iran
Article information
  • Iranian Red Crescent Medical Journal: January 31, 2019, 21 (1); e68772
  • Published Online: February 4, 2019
  • Article Type: Research Article
  • Received: March 18, 2018
  • Revised: December 29, 2018
  • Accepted: January 2, 2019
  • DOI: 10.5812/ircmj.68772

To Cite: Nafar M, Sabaghian T, Khoshdel A, Alipour B, Samavat S. Serum Calcium and Phosphorus Levels in Hemodialysis Patients: A Large Population-Based Multicenter Study, Iran Red Crescent Med J. 2019 ; 21(1):e68772. doi: 10.5812/ircmj.68772.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-18. doi: 10.1097/01.ASN.0000133041.27682.A2. [PubMed: 15284307].
  • 2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31(4):607-17. [PubMed: 9531176].
  • 3. Villain C, Ecochard R, Bouchet JL, Daugas E, Drueke TB, Hannedouche T, et al. Relative prognostic impact of nutrition, anaemia, bone metabolism and cardiovascular comorbidities in elderly haemodialysis patients. Nephrol Dial Transplant. 2018. doi: 10.1093/ndt/gfy272. [PubMed: 30202988].
  • 4. Gallieni M, Cucciniello E, D'Amaro E, Fatuzzo P, Gaggiotti A, Maringhini S, et al. Calcium, phosphate, and PTH levels in the hemodialysis population: A multicenter study. J Nephrol. 2002;15(2):165-70. [PubMed: 12018633].
  • 5. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52(3):519-30. doi: 10.1053/j.ajkd.2008.03.020. [PubMed: 18514987].
  • 6. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2004;44(5 Suppl 2):34-8. [PubMed: 15486872].
  • 7. Andrassy KM. Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'. Kidney Int. 2013;84(3):622-3. doi: 10.1038/ki.2013.243. [PubMed: 23989362].
  • 8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-130. doi: 10.1038/ki.2009.188. [PubMed: 19644521].
  • 9. National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201. [PubMed: 14520607].
  • 10. Jean G, Lataillade D, Genet L, Legrand E, Kuentz F, Moreau-Gaudry X, et al. Association between very low PTH levels and poor survival rates in haemodialysis patients: Results from the French ARNOS cohort. Nephron Clin Pract. 2011;118(2):c211-6. doi: 10.1159/000321642. [PubMed: 21178378].
  • 11. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008;73(11):1296-302. doi: 10.1038/ki.2008.64. [PubMed: 18337714].
  • 12. Neri L, Kreuzberg U, Bellocchio F, Stuard S, Barbieri C, Ketteler M. Sao030 five-year mortality and hospitalization risk associated with chronic kidney disease mineral bone disease (CKD-MBD). Nephrol Dial Transpl. 2018;33(suppl_1):i327. doi: 10.1093/ndt/gfy104.SaO030.
  • 13. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20(2):388-96. doi: 10.1681/ASN.2008060609. [PubMed: 19092121]. [PubMed Central: PMC2637053].
  • 14. Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric nutritional risk index: A new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82(4):777-83. doi: 10.1093/ajcn/82.4.777. [PubMed: 16210706].
  • 15. Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Ariet M. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm. 1983;40(6):1016-9. [PubMed: 6869387].
  • 16. Arbor Research Collaborative for Health. The DOPPS annual report. 2016. Available from: http://www.dopps.org/annualreport/.
  • 17. Kim GH, Choi BS, Cha DR, Chee DH, Hwang E, Kim HW, et al. Serum calcium and phosphorus levels in patients undergoing maintenance hemodialysis: A multicentre study in Korea. Kidney Res Clin Pract. 2014;33(1):52-7. doi: 10.1016/j.krcp.2013.12.003. [PubMed: 26877950]. [PubMed Central: PMC4714160].
  • 18. Deger SM, Mutluay R, Derici U, Mandiralioglu F, Arinsoy T, Sindel S. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients? Med Princ Pract. 2011;20(1):85-9. doi: 10.1159/000319768. [PubMed: 21160221].
  • 19. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: A survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant. 1996;11 Suppl 3:111-20. [PubMed: 8840325].
  • 20. Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis. 2001;38(6):1351-7. doi: 10.1053/ajkd.2001.29254. [PubMed: 11728974].
  • 21. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771-80. doi: 10.1038/sj.ki.5001514. [PubMed: 16820797].
  • 22. Merle E, Roth H, London GM, Jean G, Hannedouche T, Bouchet JL, et al. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. Kidney Int. 2016;89(3):666-74. doi: 10.1016/j.kint.2015.12.001. [PubMed: 26880460].
  • 23. Naves-Diaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernandez-Martin JL, Rodriguez-Puyol D, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES study. Nephrol Dial Transplant. 2011;26(6):1938-47. doi: 10.1093/ndt/gfq304. [PubMed: 20513773].
  • 24. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1943-51. [PubMed: 15213285].
  • 25. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19(9):1827-35. doi: 10.1681/ASN.2007050622. [PubMed: 18480316]. [PubMed Central: PMC2518431].
  • 26. Jean G, Mayor B, Hurot JM, Deleaval P, Lorriaux C, Zaoui E, et al. Biological impact of targeted dialysate calcium changes in haemodialysis patients: The key role of parathyroid hormone. Nephrol Dial Transplant. 2013;28(1):176-82. doi: 10.1093/ndt/gfs119. [PubMed: 22764192].
  • 27. Rambod M, Bross R, Zitterkoph J, Benner D, Pithia J, Colman S, et al. Association of malnutrition-inflammation score with quality of life and mortality in hemodialysis patients: A 5-year prospective cohort study. Am J Kidney Dis. 2009;53(2):298-309. doi: 10.1053/j.ajkd.2008.09.018. [PubMed: 19070949]. [PubMed Central: PMC5500250].
  • 28. Jean G, Lafage-Proust MH, Souberbielle JC, Granjon S, Lorriaux C, Hurot JM, et al. [How to deal with those low parathyroid hormone values in dialysis patients?]. Nephrol Ther. 2012;8(6):462-7. French. doi: 10.1016/j.nephro.2012.04.003. [PubMed: 22627198].
  • 29. Bilancio G, Lombardi C, Pisot R, Mekjavic IB, De Santo NG, Luciano MG, et al. Effects of prolonged immobilization on sequential changes in mineral and bone disease parameters. Am J Kidney Dis. 2013;61(5):845-7. doi: 10.1053/j.ajkd.2012.10.015. [PubMed: 23177703].
  • 30. Avram M, Sreedhara R, Henry A, Martínez C, Fein P. Correlates of survival in peritoneal dialysis: 15 years of follow-up. J Am Soc Nephrol. 1999;10:311A.
  • 31. Avram M, Sreedhara R, Oo K, Bista A, Mittman N. Prognostic value of enrollment nutritional markers including novel predictors PTH and prealbumin in hemodialysis patients: 12 years of follow-up. J Am Soc Nephrol. 1999;10:272A.
  • 32. Sanchez-Gonzalez MC, Lopez-Barea F, Bajo MA, Selgas R, Collaborators of the Multicenter Study G. Serum albumin levels, an additional factor implicated in hyperparathyroidism outcome in peritoneal dialysis: A prospective study with paired bone biopsies. Adv Perit Dial. 2006;22:198-202. [PubMed: 16983969].
  • 33. Akizawa T, Kinugasa E, Kurihara R. Risk factors for the development of parathyroid hormone deficiency in dialysis patients. J Am Soc Nephrol. 1998;9:561A.
  • 34. Mehrotra R, Supasyndh O, Berman N, Kaysen G, Hurst L, Leonardi M, et al. Age-related decline in serum parathyroid hormone in maintenance hemodialysis patients is independent of inflammation and dietary nutrient intake. J Ren Nutr. 2004;14(3):134-42. [PubMed: 15232791].
  • 35. Dukkipati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM, et al. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010;20(4):243-54. doi: 10.1053/j.jrn.2009.10.006. [PubMed: 20199875]. [PubMed Central: PMC3175364].
  • 36. Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: What is next? Semin Dial. 2005;18(5):365-9. doi: 10.1111/j.1525-139X.2005.00074.x. [PubMed: 16191172].
  • 37. Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP. Kidney bone disease and mortality in CKD: Revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010;(117):S10-21. doi: 10.1038/ki.2010.189. [PubMed: 20671739]. [PubMed Central: PMC5494176].
  • 38. Feroze U, Molnar MZ, Dukkipati R, Kovesdy CP, Kalantar-Zadeh K. Insights into nutritional and inflammatory aspects of low parathyroid hormone in dialysis patients. J Ren Nutr. 2011;21(1):100-4. doi: 10.1053/j.jrn.2010.10.006. [PubMed: 21195929]. [PubMed Central: PMC3032422].
  • 39. Jean G, Souberbielle JC, Zaoui E, Lorriaux C, Hurot JM, Mayor B, et al. Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients. BMC Nephrol. 2016;17(1):153. doi: 10.1186/s12882-016-0365-9. [PubMed: 27756251]. [PubMed Central: PMC5070007].
  • 40. Kovesdy CP, Kalantar-Zadeh K. Novel targets and new potential: Developments in the treatment of inflammation in chronic kidney disease. Expert Opin Investig Drugs. 2008;17(4):451-67. doi: 10.1517/13543784.17.4.451. [PubMed: 18363512]. [PubMed Central: PMC5500838].
  • 41. Poulia KA, Garcia MC, Marcelli D, Weise B. Nutrition screening practices and barriers in patients with chronic kidney disease. Results from a worldwide survey. Clinical Nutrition. 2018;37. S100. doi: 10.1016/j.clnu.2018.06.1386.
  • 42. Reilly RF. We use too much vitamin D in hemodialysis patients. Semin Dial. 2016;29(4):320-2. doi: 10.1111/sdi.12499. [PubMed: 27075415].
  • 43. Nafar M, Rashid Farokhi F, Zeraati AA, Ossareh S, Atapour A, Nemati E, et al. Clinical practices and therapeutic management of mineral and bone disorders in chronic kidney disease 4, 5 and 5D: The OCEANOS study in Iran. Nephro-Urology Monthly. 2017;10(1). e61632. doi: 10.5812/numonthly.61632.
  • 44. Mahdavi-Mazdeh M, Zamyadi M, Norouzi S, Heidary Rouchi A. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran province, Iran. Iran J Kidney Dis. 2007;1(1):25-8. [PubMed: 19357440].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments